Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2007


  • Klimm B, Eich HT, Haverkamp H, Lohri A, Koch P, Boissevain F, Trenn G, Worst P, Dühmke E, Müller RP, Müller-Hermelink K, Pfistner B, Diehl V, Engert A. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol Oct 18:357-363 (2007)
  • Sieniawski M, Staak O. Glossmann JP, Reineke T, Scheuss H, Diehl V, Engert A, Josting A. Rituximab added to an intensified salvage chemotherapy program followed by autologuous stem cell transplantation improves outcome in relapsed and refractory aggressive Non-Hodgkin-Lymphoma. Ann Hematol 86(2) February: 107-115 (2007)
  • Eichenauer DA, Simhadri VL, Pogge von Strandmann E, Ludwig A, Matthews V, Reiners KS, von Tresckow B, Saftig P, Rose-John S, Engert A, Hansen HP. ADAM10 inhibition of CD30 shedding increases specificity of targeted immunotherapy. Cancer Res 67(1) January 1:332-338 (2007)
  • Renné C, Hinsch N, Willenbrock K. Fuchs M, Klapper W, Engert A, Küppers R, Hansmann ML, Bräuninger A. The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin lymphoma. Int J Cancer 120(11) June 1:2504-9 (2007)
  • Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U. Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin’s disease and its effect on myelotoxicity. Clin Pharmacokinetics 46 (4):319-333 (2007)
  • Schulz H, Bohlius J, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A. Immunochemotherapy with Rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 99(9):706-14 (2007)
  • Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Nickelsen M, Engert A, Borchmann P. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin’s lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica 92: 568-569 (2007)
  • von Tresckow B, Pogge von Strandmann E, Sasse S, Tawadros S, Engert A, Hansen H. Simvastatin-dependent apoptosis in Hodgkin’s lymphoma cells and growth impaerment of human Hodgkin’s tumors in vivo. Haematologica 92: 682-685 (2007)
  • Greb A, Bohlius J, Trelle S, Schiefer D, De Souza C, Gisselbrecht C, Intragumtornchai T, Kaiser U, Kluin-Nelemans JC, Martelli M, Milpied NJ, Santini G, Verdonck LF, Vitolo U, Schwarzer G, Engert A. High-dose chemotherapy with autologous stem cell support in the first-line treatment of aggressive non-Hodgkin lymphoma – results of a comprehensive meta-analysis. Cancer Treat Rev 33(4) June: 338-46 (2007)
  • Ansell SM, Horwitz SM, Engert A, Khan K, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P. Phase I/II Study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma. J Clin Oncol 25(19), July 1:2764-9 (2007)
  • Rothe A, Nathanielsz A, Hosse RJ, Oberhäuser F, Pogge von Strandmann E, Engert A, Hudson PJ, Power BE. Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display. J Biotechnol 130:448-454 (2007)
  • Re D, Fuchs M, Schober T, Engert A, Diehl V. CNS involvement in Hodgkin’s lymphoma. J Clin Oncol 20;25(21):3182 (2007)
  • Eich HT, Gossmann A, Engert A, Kriz J, Bredenfeld H, Hansemann K, Skripnitchenko R, Brillant C, Pfistner B, Staar S, Diehl V, Müller RP. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s Lymphoma – analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 69(4): 1187-1192 (2007)
  • Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri V, Borchmann P, McKinnon PJ, Hallek M, Engert A. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27 (Dec 3):1-10 (2007)
  • Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V for the German Hodgkin’s Study Group (GHSG). Two cycles of ABVD plus Extended Field Radiotherapy is Superior to Radiotherapy Alone in Early-Favourable Hodgkin Lymphoma: Final Results of the GHSG HD7 Trial. J Clin Oncol 10;25(23): 3495-3502 (2007)
  • Weingart O, Rehan FA, Schulz H, Naumann F, Knauel I, Brillant C, Bohlius J, Engert A. Sixth biannual report of the Cochrane Haematological Malignancies Group – Focus on Non Hodgkin Lymphoma. J Natl Cancer Inst Sept 5;99(17):E1 (2007)


  • Klimm B, Diehl V, Engert A. Hodgkin Lymphoma in the Elderly: A different disease in patients over 60 years. Oncology (Williston Park, N.Y.) July 21(8): 982-90 (2007)
  • 2. Klimm B, Engert A. Therapiekonzepte beim Hodgkin Lymphom. Concepts of treatment in Hodgkin’s Lymphoma. Klinische Onkologie 4, 27-33 (2007/2008)
  • 3.  Diehl V, Engert A, Re D. New Strategies for the Teatment of Advanced Stage Hodgkin Lymphoma. Hematol Oncol Clin North Am Oct 21(5):897-914 (2007)